TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma

被引:5
|
作者
Mehta, Anurag [1 ]
Diwan, Himanshi [1 ]
Bansal, Divya [1 ]
Gupta, Manoj [2 ]
机构
[1] Rajiv Gandhi Canc Inst & Res Ctr RGCIRC, Dept Lab Mol & Transfus Serv, New Delhi 110085, India
[2] Rajiv Gandhi Canc Inst & Res Ctr RGCIRC, Dept Nucl Med, New Delhi, India
关键词
BRG1; Lung; Non-small cell lung carcinoma; SMARCA4; Thyroid transcription factor 1;
D O I
10.4132/jptm.2021.09.16
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non-small cell lung carcinomas. We present here a case of SD-LUAD with curious thyroid transcription factor 1 (TTF1) expression in a morphologically heterogenous lung adenocarcinoma. The better differentiated area showed preservation of TTF1 expression, and a poorly differentiated tumor had loss of TTF1 expression with universal BRG1 loss.
引用
收藏
页码:53 / 56
页数:4
相关论文
共 50 条
  • [31] The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target
    Navickas, Sophie M.
    Giles, Katherine A.
    Brettingham-Moore, Kate H.
    Taberlay, Phillippa C.
    ONCOGENE, 2023, 42 (31) : 2363 - 2373
  • [32] Dermatofibrosarcoma Protuberans and SMARCA4/BRG1 Loss: Novel Molecular Change or Coincidental Association?
    Deng, Huiyan
    Li, Mingyang
    Jia, Ying
    Jiang, Hanxu
    Jia, Keqi
    Fan, Xiaojie
    Liu, Yueping
    SAGE OPEN PATHOLOGY, 2025, 18
  • [33] Discovery of selective BRM ( SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers
    Lee, Janice Y.
    Brooks, Nathan
    Antonakos, Brandon
    Perria, Bryan
    Langan, Candace
    Jones, Bonita D.
    Flack, Robert Stephen
    Li, Zhifang
    Terry, David
    Wallace, Ross
    Bondi, Robert
    Sis, Gereint
    Baracani, Ronee
    McVean, Maralee
    Kolakowski, Gabrielle
    Osimboni, Dayo
    Wilson, Kevin
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
    Wilson, Boris G.
    Helming, Katherine C.
    Wang, Xiaofeng
    Kim, Youngha
    Vazquez, Francisca
    Jagani, Zainab
    Hahn, William C.
    Roberts, Charles W. M.
    MOLECULAR AND CELLULAR BIOLOGY, 2014, 34 (06) : 1136 - 1144
  • [35] SMARCA4/BRG1 Loss Occurs in Mediastinal and Pleural Tumors with Rhabdoid Morphology and Aggressive Behavior
    Sauter, Jennifer L.
    Graham, Rondell
    Roden, Anja C.
    Boland, Jennifer M.
    MODERN PATHOLOGY, 2017, 30 : 494A - 494A
  • [36] BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization
    Orvis, Tess
    Hepperla, Austin
    Walter, Vonn
    Song, Shujie
    Simon, Jeremy
    Parker, Joel
    Wilkerson, Matthew D.
    Desai, Nisarg
    Major, Michael B.
    Hayes, D. Neil
    Davis, Ian J.
    Weissman, Bernard
    CANCER RESEARCH, 2014, 74 (22) : 6486 - 6498
  • [37] Selective, chemically-induced degradation of BRM (SMARCA2) enables in vivo efficacy in BRG1 (SMARCA4)-deficient xenograft tumor models
    Berlin, Michael
    Cantley, Jennifer
    Wang, Jing
    Bookbinder, Mark
    Cadelina, Gregory
    Chan, Emily
    Chen, Huifen
    Chen, Xin
    Davenport, Kim
    Fernando, Tharu
    Gordon, Debbie
    Hamman, Brian
    Haskell, Roy
    Ishchenko, Alexey
    Kirkpatrick, Donald S.
    Maher, Jonathan
    Merchant, Mark
    Moffat, John
    Morgan, Alicia
    Nguyen, An
    Pizzano, Jennifer
    Quinn, Connor
    Rose, Christopher M.
    Rousseau, Emma
    Sethuraman, Vijay
    Staben, Leanna
    Wilson, Catherine
    Ye, Xiaofen
    Broccatelli, Fabio
    Yauch, Robert
    Dragovich, Peter S.
    CANCER RESEARCH, 2020, 80 (16)
  • [38] SMARCA4/BRG1 Loss Occurs in Mediastinal and Pleural Tumors with Rhabdoid Morphology and Aggressive Behavior
    Sauter, Jennifer L.
    Graham, Rondell
    Roden, Anja C.
    Boland, Jennifer M.
    LABORATORY INVESTIGATION, 2017, 97 : 494A - 494A
  • [39] Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
    Shaykevich, Aaron
    Chae, Danbee
    Silverman, Isaac
    Bassali, Jeremy
    Louloueian, Netanel
    Siegman, Alexander
    Bandyopadhyaya, Gargi
    Goel, Sanjay
    Maitra, Radhashree
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 229 - 239
  • [40] Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status
    Aaron Shaykevich
    Danbee Chae
    Isaac Silverman
    Jeremy Bassali
    Netanel Louloueian
    Alexander Siegman
    Gargi Bandyopadhyaya
    Sanjay Goel
    Radhashree Maitra
    Investigational New Drugs, 2024, 42 : 229 - 239